Drug Type Small molecule drug |
Synonyms KAN571 |
Target |
Action antagonists |
Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mantle-Cell Lymphoma | Preclinical | Sweden | 27 Oct 2022 |